Choose Your Country or Region

GW4869

Name: GW4869
Brand: Selleck Chemicals
SKU: S7609
Rating: 5 (29 reviews)

Catalog No.S7609 Synonyms: GW69A, GW554869A

For research use only.

GW4869 (GW69A, GW554869A) is a neutral, noncompetitive inhibitor of sphingomyelinase (SMase) with an IC50 of 1 μM. It is selective for N-SMase, and does not inhibit acid SMase at up to at least 150 μM.

CAS No. 6823-69-4

Selleck's GW4869 has been cited by 29 publications

Purity & Quality Control

Choose Selective Phospholipase (e.g. PLA) Inhibitors

Related Compound Libraries

Other Phospholipase (e.g. PLA) Products

U73122^New

U73122 is a potent phospholipase C (PLC) inhibitor, which reduces agonist-induced Ca²⁺ increases in platelets and PMN. U73122 potently inhibits human 5-lipoxygenase (5-LO).
Liproxstatin-1^New

Liproxstatin-1 is a potent ferroptosis inhibitor with an IC50 of 22 nM.
Epacadostat (INCB024360)^New

Epacadostat (INCB024360) is a potent and selective indoleamine 2,3-dioxygenase (IDO1) inhibitor with IC50 of 10 nM and displays high selectivity over other related enzymes such as IDO2 or tryptophan 2,3-dioxygenase (TDO).
Varespladib (LY315920)

Varespladib (LY315920) is a potent and selective human non-pancreatic secretory phospholipase A2 (hnsPLA) inhibitor with IC50 of 7 nM. Phase 3.
Tanshinone I

Tanshinone I, an active principle isolated from Salvia miltiorrhiza (Danshen), is structurally similar to tanshinone IIA and may possess similar cytotoxic effects on tumor cells.
Polydatin

Polydatin (Piceid) is a crystal component extracted from the root stem of perennial herbage Polygonum Cuspidatum Sieb.et Zucc.
Halobetasol Propionate

Halobetasol Propionate (BMY-30056, CGP-14458) is an anti-inflammatory and a dermatologic agent commonly used to treat psoriasis. Halobetasol propionate is thought to act by the induction of phospholipase A2 (PLA2) inhibitory proteins.
Clofazimine

Clofazimine (NSC-141046) is a rhimophenazine dye, originally developed for the treatment of tuberculosis, it has both antimicrobial and antiinflammatory activity, postulated mechanisms of action include intercalation of clofazimine with bacterial DNA and increasing levels of cellular phospholipase A2.
Darapladib (SB-480848)

Darapladib (SB-480848) is a reversible lipoprotein-associated phospholipase A2 (Lp-PLA2) inhibitor with IC50 of 0.25 nM. Phase 3.
Erastin

Erastin is a ferroptosis activator by acting on mitochondrial VDAC, exhibiting selectivity for tumor cells bearing oncogenic RAS. Solutions of Erastin are best fresh-prepared.

Download Inhibitor Catalog

Phospholipase (e.g. PLA) Signaling Pathways

Phospholipase (e.g. PLA) Signaling Pathway Map

Biological Activity

Description

Targets

SMase ^[1]
(Cell-free assay)

1 μM

In vitro

GW4869 inhibits N-SMase not only in vitro but also in a cellular model. GW4869 does not significantly impair TNF-induced NF-κB translocation to nuclei. Therefore, GW4869 does not interfere with other key TNF-mediated signaling effects. GW4869 is able, in a dose-dependent manner, to significantly protect from cell death as measured by nuclear condensation, caspase activation, PARP degradation, and trypan blue uptake. These protective effects are accompanied by significant inhibition of cytochrome c release from mitochondria and caspase 9 activation, therefore localizing N-SMase activation upstream of mitochondrial dysfunction. At up to 150 μM, GW4869 does not inhibit the cloned human A-SMase. GW4869 shows no or minor inhibitory activity versus other hydrolytic enzymes, such as bacterial phosphatidylcholine-PLC and bovine protein phosphatase 2A, and it shows significantly higher activity versus the rat brain enzyme compared with the human lyso-PAF PLC^[1].

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID

MCF7	NH7iZnpHfW6ldHnvckBie3OjeR?=	MWKxNE0zOCEQvF2=		MmDPeIhmKGGmZHn0bY9vKG:oIEGwJO69VSCJV{S4Olkhe2mpbnnmbYNidnSueTDpcohq[mm2ZXSgWG5HNWmwZIXj[YQhW01iaInkdo9tgXOrczyge4hmemWjczCyNEDPxE1ib3[geIhmKGOxbYDveY5lKHC{b4TlZ5Rm\CClb33wcIV1\Wy7IH\yc40hfGinIHzvd5Mhd2Zic4DobY5od227ZXzpci=>	NYjBUoM{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUKxOVQxQThpPkGyNVU1ODl6PD;hQi=>
OPM2	M2fKcnBzd2yrZnXyZZRqd25iYYPzZZk>	NULvbHI4OCxiMT6yOUwhOi53LDC1MEAyOCxiMkCsJFQxKM7:bX;sM2w>	NXTkWXMxOjRiaB?=	NH7H[WJ1cGViY3XscEBxem:uaX\ldoF1cW:wIILheIUhf2G\|IHnuZ5Jm[XOnZDDh[pRmeiCJV{S4OlkhfHKnYYTt[Y51NiCWaHWgbY5pcWKrdHnvckBw\iClZXzsJJBzd2yrZnXyZZRqd25id3HzJI9vdHlic3nncolncWOjboSge4hmdiC2aHWgZ49v[2WwdILheIlwdiCxZjDHW\|Q5Pjlid3HzJFQxKM7:bX;sM2whd3JiaHnnbIVzNg>?	MYK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDh3OEK5OEc,Ojh6NUiyPVQ9N2F-
RPMI-8226	Mnf2R4VtdCC4aXHibYxqfHliYYPzZZk>		NWnpeIpTPzJiaB?=	NY\aS41X[3m2b4TvfIlkKHSxIHGgdIFv\Wxib3[gUW0h[2WubDDsbY5mew>?	NY\pWGNIRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkiyNVE2PzNpPkK4NlEyPTd\|PD;hQi=>
NCI-H929	NEPWVnJE\WyuII\pZYJqdGm2eTDhd5NigQ>?		NY[wWWkzPzJiaB?=	NFr0V5lkgXSxdH;4bYMhfG9iYTDwZY5mdCCxZjDNUUBk\WyuIHzpcoV{	NWrZRYNuRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkiyNVE2PzNpPkK4NlEyPTd\|PD;hQi=>
JJN3	NHHrZZpE\WyuII\pZYJqdGm2eTDhd5NigQ>?		MUK3NkBp	NE[5T2NkgXSxdH;4bYMhfG9iYTDwZY5mdCCxZjDNUUBk\WyuIHzpcoV{	NHHCTlA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEKxNVU4Oyd-MkiyNVE2PzN:L3G+
U266	NWfLOG42S2WubDD2bYFjcWyrdImgZZN{[Xl?		M1LibFczKGh?	M1TkPIN6fG:2b4jpZ{B1dyCjIIDhcoVtKG:oIF3NJINmdGxibHnu[ZM>	MnfKQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh{MUG1O\|MoRjJ6MkGxOVc{RC:jPh?=
Daudi	Mn;4R4VtdCC4aXHibYxqfHliYYPzZZk>		NHP6S2w4OiCq	MXvuc5Qh[3m2b4TvfIlkKHSxIH7vck1OVSClZXzsJIxqdmW\|IH;yJHBDVUO\|	NVy5[oMzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkiyNVE2PzNpPkK4NlEyPTd\|PD;hQi=>
Jurkat	M2[zdGNmdGxidnnhZoltcXS7IHHzd4F6		MkCwO\|IhcA>?	M2r2NI5wfCCleYTveI95cWNidH:gco9vNU2PIHPlcIwhdGmwZYOgc5IhWEKPQ4O=	MVq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDJzMUW3N{c,Ojh{MUG1O\|M9N2F-
K562	M4HwOmNmdGxidnnhZoltcXS7IHHzd4F6		M{KyRVczKGh?	Mnzaco91KGO7dH;0c5hq[yC2bzDuc44uVU1iY3XscEBtcW6nczDvdkBRSk2Fcx?=	NWDXTW55RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkiyNVE2PzNpPkK4NlEyPTd\|PD;hQi=>
PBMCs	MYrD[YxtKH[rYXLpcIl1gSCjc4PhfS=>		MlLmO\|IhcA>?	NFK1SGdvd3RiY4n0c5RwgGmlIITvJI5wdi2PTTDj[YxtKGyrbnXzJI9zKFCETVPz	NFntclY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEKxNVU4Oyd-MkiyNVE2PzN:L3G+

Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID

Immunofluorescence

Nrf2

29794115

In vivo

Systemic administration of GW4869 does not alter the ceramide or sphingomylein content of liver, heart or skeletal muscle but does decrease the ceramide content and increase the sphingomyelin content in brain. Inhibition of nSMase2 with GW4869 slowed learning. Mice administered GW4869 do not progressively decrease latency to locate the hidden platform with repeated training trials, suggesting that they has difficulty learning to use spatial cues to navigate the pool^[2]. Intraperitoneal injection of GW4869 reduces the levels of brain and serum exosomes, brain ceramide, and Aβ1-42 plaque load. GW4869 reduces amyloid plaque formation in vivo by preventing exosome secretion. GW4869 may have a low toxicity at levels needed to achieve a biological effect from nSMase2 inhibition^[3].

Protocol (from reference)

Cell Research:

^[1]

Cell lines: MCF7 cells
Concentrations: 10-20 μM
Incubation Time: 30 min
Method:
MCF7 human breast cancer cells are routinely cultured in RPMI 1640 containing 10% FBS at 37 °C in 5% CO2. Unless otherwise indicated, for treatment, cells are seeded at 1.7 × 10⁶ cells/10-cm culture dish in 10 ml of complete medium; after 24 h, the medium is replaced with 7 ml of RPMI 1640 containing 2% FBS and 25 mM Hepes, pH 7.5, and the cells are rested for 2 h prior to treatment. GW4869 is routinely stored at −80 °C as a 1.5 mM stock suspension in Me2SO. Right before use, the suspension is solubilized by the addition of 5% methane sulfonic acid (MSA) (2.5 μl of 5% MSA in sterile double-distilled H2O are added to 50 μl of GW4869 stock suspension; therefore, the concentration of the GW4869 stock solution at the time of the experiments is 1.43 mM). The suspension is mixed and warmed up at 37 °C until clear. Cells are preincubated with the inhibitor for 30 min prior to treatment with TNF. Control cells are treated with Me2SO containing 5% MSA, similarly to the samples receiving the GW4869 solution. When different doses of GW4869 are tested, amounts of vehicle solution are added in order to equal the volume of GW4869 used for the highest dose.

Animal Research:

^[2]

Animal Models: Mice with a complete loss of nSMase2 activity (background: C57BL/6J mice)
Dosages: 1.25 mg/kg
Administration: i.p.

References

Solubility (25°C)

In vitro	DMSO	Insoluble . Please powderise before use.
	Water	Insoluble
	Ethanol	Insoluble

Chemical Information

Molecular Weight	577.5
Formula	C₃₀H₂₈N₆O₂.₂HCl.XH₂O
CAS No.	6823-69-4
Storage	3 years	-20°C	powder
Storage	2 years	-80°C	in solvent
Smiles	C1CN=C(N1)C2=CC=C(C=C2)NC(=O)C=CC3=CC=C(C=C3)C=CC(=O)NC4=CC=C(C=C4)C5=NCCN5.Cl.Cl

Download GW4869 SDF

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg Average weight of animals: g Dosing volume per animal:μL Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO + % + % Tween 80 + % ddH₂O

%DMSO+ %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
=	×	×

Dilution Calculator Molecular Weight Calculator

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):